Revelation Biosciences, Inc.

REVB Nasdaq SEC CIK 1810560
Follow Revelation Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.3M −73.8% vs same quarter last year
EPS, diluted −$5.92
Operating cash flow −$2.4M −48.6% vs same quarter last year
Operating income −$3.4M −74.1% vs same quarter last year
Net income by quarter
−$1.7M
−$2.1M
−$2.4M
−$1.9M
−$2.5M
−$3M
−$3.3M
−$3.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$8.9M
FY24−$15M
FY23−$120.3K
FY22−$10.8M
FY21−$12M
FY20−$1.6M
FY19−$3.6K